Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

Spotify Founder's HealthTech Startup Neko Scores $260 Million | PYMNTS.com

Jan 23, 2025 - pymnts.com
Daniel Ek, founder of Spotify, has co-founded Neko Health, a Stockholm-based startup focused on AI-powered preventative healthcare. Neko Health recently secured $260 million in Series B funding, led by Lightspeed Venture Partners, valuing the company at approximately $1.8 billion. This funding will support the company's expansion into the U.S. and follows a $65 million Series A round in July 2023. The investment will see Lightspeed's Bejul Somaia join Neko Health's board of directors. Neko Health aims to revolutionize healthcare by shifting from reactive to proactive care, using advanced technology for comprehensive full-body scans that detect health issues like skin cancer and cardiovascular risks.

The company has already completed 10,000 scans in its clinics in Stockholm and London and has a waiting list exceeding 100,000 people. Neko Health's non-invasive procedure uses over 70 sensors to collect 50 million data points, analyzed by AI to provide health insights. The recent funding will accelerate Neko's global expansion and investment in research and development. Co-founder Hjalmar Nilsonne emphasized the shift in healthcare towards proactive measures driven by technology and consumer demand, with plans to continue innovating to prevent diseases before they develop.

Key takeaways:

  • Neko Health, co-founded by Spotify's Daniel Ek, secured $260 million in Series B funding to expand its AI-powered preventative healthcare services into the U.S.
  • The funding round, led by Lightspeed Venture Partners, values Neko Health at approximately $1.8 billion and includes participation from General Catalyst, O.G. Venture Partners, Rosello, Lakestar, and Atomico.
  • Neko Health offers a comprehensive full-body scanning service that uses over 70 sensors to collect 50 million data points, analyzed by AI to assess health risks such as skin cancer and cardiovascular issues.
  • The company has completed 10,000 scans in Stockholm and London and has a waiting list of over 100,000 people, with plans for global expansion and further R&D investments.
View Full Article

Comments (0)

Be the first to comment!